🇺🇸 FDA

Company profile · Sponsor

Amylyx

Amylyx Pharmaceuticals EMEA B.V.

AMLX · NYSE pharma CAMBRIDGE, MA, EU
Pipeline
7
Drugs
1
Patents
8

Quick answer

Amylyx (AMLX) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker AMLX
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, EU
SEC CIK 0001658551

Pipeline (7)

Search pipeline →

  1. AMX0035

    Amylyx

    Progressive Supranuclear Palsy

    phase 3 small molecule completed

    1 trial

  2. AMX0035

    Amylyx

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    5 trials

  3. Avexitide

    Amylyx

    Post Bariatric Hypoglycemia

    phase 3 small molecule active

    1 trial

  4. AMX0035

    Amylyx

    ALS

    phase 2 small molecule active

    1 trial

  5. AMX0035

    Amylyx

    Wolfram Syndrome

    phase 2 small molecule active

    1 trial

  6. AMX0035

    Amylyx

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  7. AMX0114

    Amylyx

    ALS

    phase 1 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. sodium phenylbutyrate

    AMMONAPS

    ORAL approved

    A16AX03

Patents (8)

Search patents →

  1. US 12246027

    Compositions of bile acids and phenylbutyrate compounds

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12186330

    Compositions for improving cell viability and methods of use thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12138272

    Methods and compositions for treating amyotrophic lateral sclerosis

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11583542

    Compositions of bile acids and phenylbutyrate compounds

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11559533

    Compositions of bile acids and phenylbutyrate compounds

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11071742

    Compositions for improving cell viability and methods of use thereof

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10857162

    Compositions for improving cell viability and methods of use thereof

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10251896

    Compositions for improving cell viability and methods of use thereof

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Amylyx?

Amylyx (AMLX) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Amylyx sponsor?

We track 7 ClinicalTrials.gov-linked programs for Amylyx, including AMX0035 and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Amylyx company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.